ClinicalTrials.gg
RecruitingNCT07133880Updated Oct 19, 2026

Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators

A Phase 4 interventional study of umeclidinium 62.5 µg and vilanterol 25 µg and Revefenacin 175 µg, Formoterol 20 µg in COPD (Chronic Obstructive Pulmonary Disease), sponsored by University of Tennessee Graduate School of Medicine. Recruiting at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by University of Tennessee Graduate School of Medicine · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Dec 2023, registered Aug 2025).
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, none of them phase 3. GSK573719 · Pulmonary Disease, Chronic Obstructive.

Planned enrollment
27th of 43
72 · median 131
Started
2023
with 2 others
Phase 4
13 of 43
3 open now
Registered
41st of 43
by date
Lead sponsor
1 of 43
University of Tennessee Graduate School of Medicine

Among the 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive, this one is the 27th largest by planned enrollment, is one of 3 that started in 2023, is one of 13 in phase 4, and was the 41st registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About GSK573719

GSK573719: first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this study is to compare the effectiveness of inhaled bronchodilators delivered via nebulizers vs. dry powder inhalers (DPIs) in symptomatic participants with Chronic Obstructive Pulmonary Disease (COPD) who have airflow obstruction (FEV1/FVC ≤ 70%) and show significant air trapping (RV ≥ 120% of predicted).

The investigators hypothesize that, in patients with symptomatic COPD, therapy with a long-acting anti muscarinic agent/long-acting beta agonist (LAMA/LABA) combination administered by nebulizer will improve hyperinflation (increase in inspiratory capacity and reduction in residual volume) and reduce symptoms related to COPD to a greater extent than LAMA/LABA therapy given by a DPI.

The study aims to demonstrate the following:

  1. Compare the values of inspiratory capacity (IC) and residual volume (RV) in patients receiving LAMA/LABA by DPI with those receiving LAMA/LABA by nebulizer
  2. Compare patient reported outcomes (COPD Assessment Test (CAT score), Baseline/Transition Dyspnea Index (BDI/TDI) and the St. George Respiratory Questionnaire (SGRQ) in symptomatic patients with COPD receiving LAMA/LABA by DPI with those receiving LAMA/LABA by nebulizer
Read the detailed description

This is a prospective, randomized, parallel group, double dummy, phase four, 13-week clinical trial with 1:1 allocation comparing long-acting anti-muscarinic agent (LAMA; Umeclidinium 62.5 μg once daily) and long acting beta-agonist (LABA; Vilanterol 25 μg once daily) delivered by DPI (Group A), vs a nebulized LAMA/LABA combination (revefenacin 175 μg once daily and formoterol 20 μg twice daily) (Group B) among symptomatic subjects with stable COPD.

The study begins with a screening visit and run-in period. Patients who are eligible and willing to participate will sign informed consent. They will be trained on the use of the DPI and nebulizer, as well as completion of the daily diary (symptom and medication logs) and questionnaires (CAT, BDI/TDI, SGRQ). Vital signs and a physical examination will be performed, and inspiratory flow rate will be determined using the In-Check DIAL. Medications will be adjusted to ensure clinical stability prior to randomization.

Baseline Study Visit 2 occurs within one week of the screening visit. Prior to this visit, participants must not have taken study medication within 48 hours or rescue medication within 6 hours of pulmonary function testing; otherwise, the visit will be rescheduled. At this visit, medical history, current medications, and adverse events are reviewed. Compliance with the daily diary (symptom and medication logs) is assessed, and participants must demonstrate ≥80% completion to continue. Participants complete CAT, BDI, and SGRQ questionnaires, undergo physical examination and vital sign measurement, and perform baseline pulmonary function testing in a plethysmograph. Eligible participants are then randomized 1:1 to receive either active drugs via DPI (Group A) or nebulizer (Group B), with treatment assignments generated using permuted blocks. Group A receives Anoro Ellipta DPI plus nebulized Revefenacin and Formoterol placebos, while Group B receives nebulized Revefenacin and Formoterol plus placebo DPI. The nebulizer is always administered first, followed by the DPI; Time 0 is defined as the end of DPI administration. Post-dose, vital signs and pulmonary function tests are conducted at 1, 2, 4, and 6 hours. Participants also receive training on diary use, study drug/device administration, and medication compliance, and they begin the assigned treatment for 12 weeks with morning and evening doses as per group assignment.

Following Visit 2, patients will continue their assigned treatments twice daily for 12 weeks. Telephone follow-ups will occur at weeks 4 and 8 (Phone Visits 1 and 2) to monitor symptoms, adverse events, and medication adherence, with administration of additional questionnaires.

The final Study Visit 3 will take place at week 12 and will include repeat pulmonary function testing pre-dose and at 1, 2, 4, and 6 hours post-dose, symptom questionnaires, vital signs, and adverse event assessment. Throughout the study, patients will maintain daily symptom diaries, including CAT scores.

03

Conditions studied

  • COPD (Chronic Obstructive Pulmonary Disease)

Keywords

  • Chronic Obstructive Pulmonary Disease
  • COPD
  • Nebulizer
  • Dry Powder Inhaler
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age > 40 years
  2. Either sex
  3. Current smoker or past cigarette smoking history of > 10 pack-years
  4. Symptoms of (cough, sputum production, shortness of breath)
  5. Modified Medical Research Council Dyspnea Scale (mMRC) score ≥2 or CAT score ≥10 at Screening/Run-in visit
  6. A PIFR > 30 at screening
  7. /FVC ratio \< 70% (within the past 12 months)
  8. Residual volume (RV) ≥ 120% predicted (within the past 12 months

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of asthma (Verification via medical record and/or patient report)
  2. Previously diagnosed atrial fibrillation with rapid ventricular response (heart rate > 110 bpm) or ventricular arrhythmia (ventricular tachycardia) (Verification via medical record and/or patient report)
  3. Acute myocardial infarction within 12 weeks of patient study registration (Verification via medical record and/or patient report)
  4. Acute exacerbation of congestive heart failure (Verification via medical record and/or patient report)
  5. Acute exacerbation of within 8 weeks (Verification via medical record and/or patient report)
  6. Recent (within 8 weeks) h/o eye surgery (Verification via medical record and/or patient report)
  7. Uncontrolled glaucoma (Verification via medical record and/or patient report)
  8. Known diagnosis of liver cirrhosis (Verification via medical record and/or patient report)
  9. Known diagnosis of chronic renal insufficiency (defined as a previous serum creatinine > 2.5 mg/dL - Verification via medical record and/or patient report)
  10. Intolerance to any of the study drugs
  11. Patients receiving long-term azithromycin
  12. Planned surgery requiring hospital admission within 3 months
  13. Currently enrolled in a pulmonary rehabilitation program
  14. Inability to give
  15. Pregnant or nursing women or women of not using a medically approved means of (i.e., oral contraceptives, intrauterine devices, diaphragm, or subdermal implants)
  16. Inability to understand instructions or comply with the study protocol
  17. Participation in another drug clinical trial within 30 days of patient study registration

Medical history can be confirmed by medical records and/or verbal confirmation from patients. However, Inclusion criteria 6 \& 7 must be verified by a previous PFT report dated within 6 months of screening

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
72 participants (estimated)

Study arms

  • Active comparator
    DPI Treatment Group

    Group A: Receives Umeclidinium 62.5 µg and Vilanterol 25 µg via DPI and Revefenacin placebo and formoterol placebo (sterile normal saline) via nebulizer at treatment visit # 2 and will continue with assigned treatment and placebo for 12 weeks

    Drug: umeclidinium 62.5 µg and vilanterol 25 µg · Drug: Placebo ( Revefenacin and Formoterol )

  • Active comparator
    Nebulizer Treatment Group

    Group B: Receives revefenacin 175 µg and formoterol 20 µg via nebulizer and placebo DPI at treatment visit # 2 and will continue with assigned treatment and placebo for 12 weeks

    Drug: Revefenacin 175 µg, Formoterol 20 µg · Drug: Placebo DPI

Interventions

  • Drugumeclidinium 62.5 µg and vilanterol 25 µg

    Drug page: GSK573719Studies of GSK573719GSK573719 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    DPI Treatment

    Also known as: Anoro Ellipta

  • DrugRevefenacinStudies of RevefenacinRevefenacin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Nebulizer Treatment

    Also known as: Yupelri, Perforomist

  • DrugPlacebo ( Revefenacin and Formoterol )

    Placebo Nebulizer Treatment

    Also known as: Normal Saline

  • DrugPlacebo DPI

    Placebo DPI Treatment

06

What researchers measure

Primary outcomes

  1. Difference Between the Values of Area Under the Response Curve for Inspiratory Capacity (IC)

    Difference between the values of area under the response curve for inspiratory capacity (IC) from baseline through six hours (AUC IC 0-6h) after inhalation of LAMA/LABA combination with a nebulizer versus a DPI OR Proportion of participants achieving improvement of \>2 points in their CAT score compared to baseline OR Proportion of participants achieving reduction of 4 points in SGRQ score compared to baseline

    Time frame: From baseline (Visit 2, Week 2) through study completion (Visit 3, Week 12)

Secondary outcomes

  1. Percentage change in Residual Volume (RV) from baseline after inhalation of LAMA/LABA combination with a nebulizer versus a DPI

    Time frame: From pre-dose (baseline measurement) to post-dose measurements at 1, 2, 4, and 6 hours during study visit 2 (Week 2) and study visit 3 (Week 12)

  2. Percentage change in Total Lung Capacity (TLC) from baseline after inhalation of LAMA/LABA combination with a nebulizer versus a DPI

    Time frame: From pre-dose (baseline measurement) to post-dose measurements at 1, 2, 4, and 6 hours during study visit 2 (Week 2) and study visit 3 (Week 12)

  3. Percentage change in airway resistance (Raw) from baseline after inhalation of LAMA/LABA combination with a nebulizer versus a DPI

    Time frame: From pre-dose (baseline measurement) to post-dose measurements at 1, 2, 4, and 6 hours during study visit 2 (Week 2) and study visit 3 (Week 12)

  4. Maximum percentage change in inspiratory capacity between 0 and 6 hours after LAMA/LABA combination with a nebulizer versus a DPI

    Time frame: From pre-dose (baseline measurement) to post-dose measurements at 1, 2, 4, and 6 hours during study visit 2 (Week 2) and study visit 3 (Week 12)

  5. Maximum percentage change in RV between 0 and 6 hours after LAMA/LABA combination

    Time frame: From pre-dose (baseline measurement) to post-dose measurements at 1, 2, 4, and 6 hours during study visit 2 (Week 2) and study visit 3 (Week 12)

  6. Maximum Percentage Change in Airway Resistance (Raw) between 0 and 6 hours after LAMA/LABA

    Time frame: From pre-dose (baseline measurement) to post-dose measurements at 1, 2, 4, and 6 hours during study visit 2 (Week 2) and study visit 3 (Week 12)

  7. Correlation of peak inspiratory flow rate with peak IC change from baseline

    Time frame: From pre-dose (baseline measurement) to post-dose measurements at 1, 2, 4, and 6 hours during study visit 2 (Week 2) and study visit 3 (Week 12)

  8. Comparison of CAT scores in patients receiving medications with DPI vs nebulizer

    Time frame: From baseline (Visit 2, Week 2) through study completion (Visit 3, Week 12)

  9. Comparison of SGRQ scores in patients receiving medications with DPI vs nebulizer

    Time frame: At baseline (Visit 2, Week 2), and at study completion (Visit 3, Week 12)

  10. Change in TDI in patients receiving medications with DPI vs nebulizer

    Time frame: Measured at Week 4 (Phone Visit 1), Week 8 (Phone Visit 2), and Week 12 (Study Visit 3)

  11. Change in CAT scores in patients receiving medications with DPI vs nebulizer

    Time frame: From baseline (Visit 2, Week 2) through study completion (Visit 3, Week 12)

  12. Change in SGRQ scores in patients receiving medications with DPI vs nebulizer

    Time frame: Measured at study visit 2 at week 2 and study completion visit 3 at week 12

  13. Correlation of CAT with LF and LH change (inspiratory capacity and residual volume change) with patient-reported outcomes including the SGRQ and the TDI

    Time frame: Baseline (Visit 2) through Study Completion (Visit 3 / Week 12)

  14. Correlation of LH with patient-reported outcomes including scores from the CAT, SGRQ and TDI

    Time frame: Baseline (Visit 2) through Study Completion (Visit 3 / Week 12)

07

Study locations

1 of 1 sites recruiting
  • The University of Tennessee Graduate School of Medicine
    Knoxville, Tennessee 37920, United States
    Recruiting
    • Tracy Walker, Study Coordinator · Contacttwalker5@utmck.edu · 865-305-4297
    • Rajiv Dhand, MD · Principal investigator
    • Isaac Biney, MD · Sub investigator
    • Samuel Treat, MD · Sub investigator
    • Paul Terry, PhD · Sub investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.

Of 86 non-industry phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 35 months is above that.

Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2025
First posted
Aug 21, 2025
StartActual
Dec 5, 2023
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: documents and verification date
1 update, last Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Minor edits only
    + 2 other changes: documents and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07133880
Lead sponsor
University of Tennessee Graduate School of Medicine
Responsible party
Sponsor
First posted
Aug 21, 2025
Start date
Dec 5, 2023
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Oct 19, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: GSK573719 · Revefenacin

Start the discussion